Eliminating Uncertainty in Coronary Artery Disease

Projektinformationen

EU-CAD

ID Finanzhilfevereinbarung: 960899

DOI

10.3030/960899

Projekt abgeschlossen

EK-Unterschriftsdatum 19 August 2020

Startdatum 1 August 2020

Enddatum 31 Juli 2022

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 3 572 775,00

EU-Beitrag

€ 2 500 000,00

Koordiniert durch

MEDTRACE PHARMA A/S
Denmark

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Leistungen

Demonstrators, pilots, prototypes (1)

2.2 Code and Infrastructure Validation

Based on Deliverable 2.2. the new aQuant code and infrastructure will be tested at selected hospitals in Europe and validated according to EU regulatory standards as well as operational specifications defined in deliverable 2.1.

Documents, reports (2)

3.2 Regulatory Approval EU

Founded on deliverable 31 the subsequent focus is to apply for and achieve regulatory approval for the MedTrace solution in the EU in the form a CEmark as medical device of the software and the medical device part of the hardware

3.1 Clinical Study EU

"In order to approve the MedTrace solution as medical device, the company needs to carry out a minor clinical study using 15O-water in cardiac patients to prove safety and efficacy. Part of this study is to purchase already existing data from Amsterdam University Medical Centers from a recent similar clinical trial. In parallel the clinical study will be prepared (study protocol, site recruitment, clinical trial agreements and patient recruitment) End deliverable is ""last patient scanned""."

Veröffentlichungen

Other (3)

Initial Experience with routine 15O-water cardiac PET workflow

Autoren: Susanne Hansen, Jeppe Madsen, Shakti Nicolai Johansen, Charlotte Jensen, Lone Winkler, Lars Gormsen and Lars Tolbod, ,
Veröffentlicht in: Journal of Nuclear Medicine, Ausgabe May 2021, 62 (supplement 1), 2021, Seite(n) 3001, ISSN 2047-2412
Herausgeber: SNM

Cardiac viability PET using combined parametric 15O-water blood flow/18F-FDG metabolism compares well with 82Rb/18F-FDG

Autoren: Mette Kjaerulff, Simon Madsen, Kirsten Bouchelouche, Lars Gormsen and Lars Tolbod
Veröffentlicht in: Journal of Nuclear Medicine, Ausgabe May 2021, 62 (supplement 1), 2021, Seite(n) 1632
Herausgeber: SNMMI

Routine clinical use of 15O-water cardiac PET: Initial experience with a novel automated solution

Autoren: LP Tolbod, LC Gormsen
Veröffentlicht in: European Heart Journal - Cardiovascular Imaging, Ausgabe Volume 22, Ausgabe Supplement_3, June 2021, 2021
Herausgeber: European Society of Cardiology
DOI: 10.1093/ehjci/jeab111.029